Videos

Experts discussed safety and efficacy data of cilta-cel for R/R MM from the CARTITUDE-1 and CARTITUDE-2 studies.

Eric Crombez, PhD, senior vice president and chief medical officer of Ultragenyx Gene Therapy, discussed indications the company is targeting.

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed future research the company plans to pursue.

Experts discuss emerging agents in the pipeline for the treatment of RRMM; including BCMA-targeted bispecific antibodies.

The hematologist from UC Health discussed the role of allogeneic stem cell transplant at first remission based on risk stratification.

The associate professor from The University of Texas MD Anderson Cancer Center discussed future research with CAR T therapy in multiple myeloma.

Experts discussed data from trials in lymphoma presented at ASCO 2021.

The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.

The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.

The research director at the Moran Eye Center discussed the genetics of developing age-related macular degeneration.

The professor of medicine from Duke University School of Medicine discussed treatment approaches for after relapse on CAR T cell therapy or for patients who are ineligible for CAR T therapy.

Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the different initiatives the company is conducting in Dravet syndrome.

The medical oncologist from Memorial Sloan Kettering Cancer Center discussed efforts made to address areas of unmet need in mantle cell lymphoma.

Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

Nina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

The chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.

Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.

Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.

The chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.

The professor from the University of Texas Anderson Cancer Center discussed challenges surrounding CAR T-cell therapy for the treatment of follicular lymphoma and other lymphomas.

The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.

The lymphoma specialist from Moffitt Cancer Center discussed the advantages of CAR T-cell therapy in non-Hodgkin lymphoma.

Magali Taiel, MD, chief medical officer, GenSight Biologics, discussed the company’s work in ophthalmic diseases.

The chief executive and chief medical officer of Celyad Oncology discussed the advantages of allogeneic CAR T therapies over autologous ones.

The executive director of the Steele Center for Translational Medicine at the Moran Eye Center discussed the research his team has been conducting in AMD.

The professor of clinical medicine, director, Multiple Myeloma and Amyloidosis Program, New York-Presbyterian Hospital, discussed utility of cellular therapies in multiple myeloma.

Experts discuss the use and selection of CAR T therapies in relapsed/refractory diffuse large B-cell lymphoma.

Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the company’s gene therapy pipeline, including their lead program ETX101.